Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

Trial Profile

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Cisplatin (Primary) ; Erlotinib (Primary) ; Pemetrexed (Primary) ; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment Because of reconsideration of using erlotinib (EGFR Tyrosine kinase inhibitor) as adjuvant aim .
    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top